Molecular sequelae of proteasome inhibition in human multiple myeloma cells
By N. Mitsiades, C. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis, Xuesong Gu, Charles Bailey, Marie G. Joseph, T. Libermann, S. Treon and 4 more. Proceedings of the National Academy of Sciences of the United States of America, 2002
787 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/069e380a476885508c2f6a322d6d21aed54afa80
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Guido Kroemer
- P. Boya
- P. Codogno
- P. Richardson
- T. Hideshima
- Philippe Dessen
- Stuart K. Calderwood
- T. Yoshimori
In Oncology
Citations in the corpus
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. (2003, methodology): “1S cells were therefore (1) pretreated with doxorubicin for 24 hours and then treated with PS-341 for an additional 24 hours, (2) pretreated with PS-341 for 24 hours and then treated with doxorubicin for an additional 24 hours, or (3) treated concomitantly with PS-341 and doxorubicin for 24 hours.”
- BET bromodomain inhibition as a therapeutic strategy to target c-Myc (2011, neutral): “…factors features prominently in the biology of MM, including NF-kB (Keats et al., 2007), c-Maf (Hurt et al., 2004), XBP1 (Claudio et al., 2002), HSF1 (Mitsiades et al., 2002), GR (Gomi et al., 1990), IRF4 (Shaffer et al., 2008), Myb (Palumbo et al., 1989), and, notably, c-Myc (Dean et al., 1983).”
- Inhibition of Macroautophagy Triggers Apoptosis (2005, background): “In addition, or alternatively, the inhibition of autophagy might alter the equilibrium state between pro- and antiapoptotic mediators with different half-lives, much as this has been shown for proteasome inhibition, a manipulation that induces apoptosis via multiple (and perhaps inextricable) pathwa”
- Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007, background): “Our microarray profiling shows that bortezomib induces HSP90 gene transcripts in human multiple myeloma cell”
- Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications (2005, background): “…elimination of cancer cells Hsp90 Chiosis et al (2001) Molecule that binds Hsp90 causes HER-2 degradation, growth arrest, and differen- tiation of bcc Mitsiades et al (2002) Effect of proteasome inhibitor PS-341 in cancer cells Lee et al (2002) Radicicol (Hsp90 inhibitor)-induced degradation of…”
- Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. (2007, background): “These results suggest that with both compounds, recovery of proteasome activity is due primarily to induction of mRNA transcription and de novo proteasome synthesis (31, 32).”